Fig. 1 · Structure

Documents & Downloads

Asiatic acid

Cat. No. A10092 CAS 464-92-6

Anti-inflammatory agent

Asiatic acid is commonly used in wound healing. Asiatic acid has antioxidant, anti-inflammatory and neuroprotective properties. Asiatic acid derivative synthesis can be used as Anticancer agents; Glycogen phosphorylase inhibitors; Hepatoprotectants.

In Stock

Publications for Asiatic acid

1 publication citing this product

  1. Rakhi Mishra, .et al. , Indian J Res Homoeopathy, 2022, Sep 27

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Asiatic acid has been studied as a modulator of cellular p38 and ERK signaling. In MCF-7 and MDA-MB-231 cells, 10 µM asiatic acid increased p38 and ERK1/2 phosphorylation. Inhibitor and siRNA experiments linked p38 to S–G2/M accumulation and ERK to apoptosis. These cellular findings do not establish direct binding to either kinase. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p38 MAPK

Cellular Effect

Cell Line Activity Value Description Reference
518A2 EC50 21.9 μM Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay [PMID: 30278332]
8505C EC50 16.8 μM Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay [PMID: 30278332]
A2780 EC50 28.2 μM Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay [PMID: 30278332]
A-375 IC50 50.33 μM Cytotoxicity against human A375 cells after 72 hrs by MTT assay [PMID: 26974379]
A549 IC50 > 100 μM Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay [PMID: 26343825]
A549 IC50 > 20 μM Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer [PMID: 31057738]
A549 IC50 18.8 μM Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay [PMID: 28754470]
A549 EC50 26.2 μM Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay [PMID: 30278332]
A549 IC50 37.81 μM Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 28754470]
A549 IC50 41.02 μM Cytotoxicity against human A549 cells after 48 hrs by MTT assay [PMID: 31057738]
BJ IC50 88.7 μM Cytotoxicity against human BJ cells after 72 hrs by MTT assay [PMID: 26974379]
CHO EC50 > 10 μM Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay [PMID: 19911773]
COS-1 EC50 0 μM Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay [PMID: 19911773]
Epithelial cell IC50 > 20 μM Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay [PMID: 18826277]
H9 IC50 9 μg/mL Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA [PMID: 9748372]
HeLa IC50 37.26 μM Cytotoxicity against human HeLa cells after 48 hrs by MTT assay [PMID: 25151580]
HeLa IC50 4 μM Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay [PMID: 28754470]
HeLa IC50 52.47 μM Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 28754470]
HeLa IC50 52.47 μM Cytotoxicity against human HeLa cells after 72 hrs by MTT assay [PMID: 26974379]
HeLa IC50 91.07 μM Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay [PMID: 26343825]

20 records · Scroll to view more

Asiatic acid Research Summary

This section summarizes 4 in vitro studies of Asiatic acid from 2 published references. In vitro models include human MCF-7 and MDA-MB-231 breast-cancer cells; T24, HepG2, A549, NCI-H460 and HL-7702 cells.

Asiatic acid In Vitro Studies

Cellular activity varies with model and assay. Asiatic acid inhibited the 48 h XTT growth readout in breast-cancer cells, while a separate A549 NF-κB reporter assay reported IC50 >20 µM. Synthetic asiatic-acid derivatives in the latter paper were evaluated separately and their binding results should not be attributed to the parent compound. [1,2]

Growth inhibition in breast-cancer cells

Cell-based study · Human MCF-7 and MDA-MB-231 breast-cancer cells [1]

Asiatic acid reduced the XTT proliferation readout after 48 h. The reported IC50 was lower in MCF-7 than in MDA-MB-231 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MCF-7 cell-growth inhibitionIC50 5.95 µM[1]
MDA-MB-231 cell-growth inhibitionIC50 8.12 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 2.5, 5, 10 and 20 µM
Exposure duration
48 h
Method
Cell exposure followed by XTT measurement
Vehicle
Solvent control; DMSO identified elsewhere in the same manuscript, but its final concentration in the XTT assay is not specified.
Co-treatment
Asiatic acid alone
Reported limits
No IC50 uncertainty estimate reported; final solvent percentage not specified. Figure 1 legend reports three determinations, mean ± SD for plotted values.
Methods and source locations

Compound reported in the paper: Asiatic acid; Compound label in the paper: Asiatic acid

Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.

Manuscript pp. 9–10 and 15; Figure 1A (p. 42), legend p. 37

MCF-7 cell-growth inhibition: XTT assay — Manuscript p. 10, Cell proliferation assay; p. 15, first Results paragraph; Figure 1A and legend p. 37

MDA-MB-231 cell-growth inhibition: XTT assay — Manuscript p. 10, Cell proliferation assay; p. 15, first Results paragraph; Figure 1A and legend p. 37

p38 and ERK pathway involvement in cell-cycle arrest and apoptosis

Cell-based study · Human MCF-7 and MDA-MB-231 breast-cancer cells [1]

Asiatic acid increased p38 and ERK1/2 phosphorylation without comparable JNK activation. Pharmacological inhibition and siRNA experiments supported p38 involvement in S–G2/M accumulation and ERK involvement in apoptosis. U0126 reduced apoptosis without significantly reversing S–G2/M accumulation; SB203580 delayed rather than abolished apoptosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p38 and ERK1/2 activation; JNK comparisonQualitative response Increased p38 and ERK1/2 phosphorylation; no corresponding JNK activation reported[1]
Dependence of cell-cycle and apoptotic responses on p38 and ERK signalingPerturbation response p38 inhibition attenuated S–G2/M accumulation; ERK inhibition attenuated apoptosis; SB203580 delayed apoptosis[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM asiatic acid; inhibitor arms used 20 µM SB203580 or U0126
Exposure duration
Phosphorylation: 1, 3, 6 and 12 h; inhibitor pretreatment: 1 h; cell-cycle readout: 12 h; apoptosis readouts: 24 and 48 h
Method
Cellular exposure with matched controls, pharmacological inhibition and siRNA perturbation
Vehicle
Equal-volume DMSO control for Figure 4; final percentage not specified.
Co-treatment
Separate SB203580 or U0126 co-treatment arms and separate p38 or ERK2 siRNA arms; not a combined therapeutic regimen.
Reported limits
Final DMSO percentage and siRNA concentration not specified in the selected manuscript methods. Numeric fold changes were not inferred from blots or bars.
Methods and source locations

Compound reported in the paper: Asiatic acid; Compound label in the paper: Asiatic acid

Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.

Manuscript pp. 9, 11–14, 19–23; Figures 4, 5 and 8; legends pp. 39–41

p38 and ERK1/2 activation; JNK comparison: Immunoblotting and cellular kinase-activity assays — Manuscript pp. 19–20; Figure 4A–B (p. 45), legend p. 39

Dependence of cell-cycle and apoptotic responses on p38 and ERK signaling: Flow cytometry and nucleosome ELISA with chemical inhibitors; p38/ERK2 siRNA corroboration — Manuscript pp. 20–23; Figures 5B–D and 8C,E (pp. 46,49); legends pp. 39–41

Limited inhibition in an NF-κB reporter assay

Cell-based study · Human A549 cells with an NF-κB luciferase reporter, stimulated with TNF-α [2]

Parent asiatic acid had a reported NF-κB reporter IC50 >20 µM. The high-affinity binding and stronger activity reported for derivative 6k do not describe asiatic acid.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of TNF-α-induced NF-κB transcriptional activityIC50 >20 µM[2]

Literature-Reported Treatment Conditions

Exposure duration
7 h co-treatment
Method
Reporter assay with TNF-α (15 ng/mL); TNF-α-only and unstimulated controls; IMD-0354 reference inhibitor
Vehicle
Not specified in the reporter methods.
Co-treatment
TNF-α stimulation; no anticancer-drug combination.
Reported limits
Exact AA test-concentration series and vehicle not specified. The >20 µM result is a potency bound, not a dosing instruction.
Methods and source locations

Compound reported in the paper: Asiatic acid; Compound label in the paper: AA (compound 1)

Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.

Table 1, AA row and footnote; NF-κB reporter Results and Experimental methods; General; Scheme 1

Inhibition of TNF-α-induced NF-κB transcriptional activity: Bright-Glo luciferase reporter assay; signal corrected for background and cell viability — Table 1, AA row; Experimental methods, In vitro inhibition of TNF-a-induced NF-κB activation in A549 lung cells

Cytotoxicity across a cell-line panel

Cell-based study · T24, HepG2, A549, NCI-H460 and HL-7702 cells [2]

The 48 h MTT panel reported asiatic acid IC50 values of 35.37–44.82 µM in four tumor cell lines and >50 µM in HL-7702. The reported ± terms have an ambiguous statistical definition in the paper.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
T24 viability reductionIC50 43.97 ± 1.36 µM[2]
HepG2 viability reductionIC50 35.37 ± 1.47 µM[2]
A549 viability reductionIC50 41.02 ± 0.78 µM[2]
NCI-H460 viability reductionIC50 44.82 ± 1.25 µM[2]
HL-7702 viability reductionIC50 >50 µM[2]

Literature-Reported Treatment Conditions

Exposure duration
48 h exposure
Method
MTT viability assay; doxorubicin reference comparator
Vehicle
Treatment vehicle not specified; DMSO used during MTT processing must not be assumed to be the dosing vehicle.
Co-treatment
Asiatic acid alone; doxorubicin was a separate comparator.
Reported limits
Exact AA concentration series and treatment vehicle not specified. Table footnote says mean ± SD but defines SD as standard error of the mean; dispersion type remains unresolved.
Methods and source locations

Compound reported in the paper: Asiatic acid; Compound label in the paper: AA (compound 1)

Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.

Table 2, AA row and footnotes; Experimental methods, Cytotoxicity assay; General; Scheme 1

T24 viability reduction: MTT assay — Table 2, AA row, T24 column and footnote a; Experimental methods, Cytotoxicity assay

HepG2 viability reduction: MTT assay — Table 2, AA row, HepG2 column and footnote a; Experimental methods, Cytotoxicity assay

A549 viability reduction: MTT assay — Table 2, AA row, A549 column and footnote a; Experimental methods, Cytotoxicity assay

NCI-H460 viability reduction: MTT assay — Table 2, AA row, NCI-H460 column and footnote a; Experimental methods, Cytotoxicity assay

HL-7702 viability reduction: MTT assay — Table 2, AA row, HL-7702 column and footnote a; Experimental methods, Cytotoxicity assay

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 464-92-6
Applications Anti-inflammatory agent
Formula C30H48O5
Molecular Weight 488.7
SMILES
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 94 mg/mL (192.34 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Asiatic acid Research References

  1. [1] Hsu YL, Kuo PL, Lin LT, et al. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. The Journal of pharmacology and experimental therapeutics (2005). PMID: 15626723 DOI: 10.1124/jpet.104.078808 Source material
  2. [2] Huang RZ, Liang GB, Li MS, et al. Synthesis and discovery of asiatic acid based 1,2,3-triazole derivatives as antitumor agents blocking NF-κB activation and cell migration. MedChemComm (2019). PMID: 31057738 DOI: 10.1039/c8md00620b Source material

Publications

1 publication citing this product

  1. Rakhi Mishra, .et al. , Indian J Res Homoeopathy, 2022, Sep 27

Added to your cart

View Cart Checkout
Loading...